avn-944
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2006 (NCT00273936)
Timeline
Indications
Mechanism of action
IMPDH1 inhibitor
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1- Mol. weight
- 477.52 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3349001 ↗
Also known as
- avn944
- avn944
- avn944
- avn 944
- avn-944
- carbamic acid, ((1s)-1-(3-((((3-methoxy-4-(5-oxazolyl)phenyl)amino)carbonyl)amino)phenyl)ethyl)-, (1r)-1-(cyanomethyl)propyl ester
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00923728 | N/A | Apr 1, 2009 | National Cancer Institute (NCI), Vertex |
| NCT00493441 | Phase 2 | Jun 1, 2007 | Vertex |
| NCT00273936 | Phase 1 | Jan 1, 2006 | Vertex |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vertex | For profit | 3 | 3 | 3 | 2006 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1